Cancer of Ovary, Cancer of the Ovary, Neoplasms, Ovarian, Ovarian Cancer, Ovary Cancer, Ovary Neoplasms
Conditions
Brief summary
The investigators propose to evaluate the feasibility, safety, and preliminary efficacy of delivering online, adaptive magnetic resonance imaging (MRI)-guided and gated stereotactic body radiation therapy for patients with recurrent or metastatic ovarian cancer on a novel, integrated Co-60 MRI treatment machine. To best assess this technology, the investigators will focus on patients that have no more than three sites of progressive disease within the central thorax, liver, and/or non-liver abdominopelvis to receive adaptive, MRI-guided and gated SBRT with MRI simulation. Patients will be treated in five fractions over one to two weeks. By adhering to strict normal tissue constraints, expected toxicity will be within the current standard of care but will allow adaptation based on daily anatomic changes. The prescription dose will be determined based on hard normal tissue constraints, and capped at 10Gy per fraction. Although the long term goal will be to achieve improved local control and disease-free survival with reduced toxicity, the present study will be driven by the short term goal of demonstrating the feasibility of this novel treatment approach for recurrent or metastatic ovarian cancer.
Interventions
DEVICEMRI-guided SBRT
BEHAVIORALEORTC QLQ-C30 Questionnaire
30 questions with 28 questions having answers that range from 1 (not at all) to 4 (very much) and the other 2 questions have answers that range from 1 (very poor) to 7 (excellent)
BEHAVIORALEORTC QLQ-OV28 Questionnaire
28 questions having answers that range from 1 (not at all) to 4 (very much)
Sponsors
Washington University School of Medicine
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologically or cytologically confirmed primary disease histology of solid ovarian, fallopian tube, or primary peritoneal tumor categorization. * Deemed medically fit for stereotactic body radiation therapy by the treating physician. * At least 18 years old. * Karnofsky Performance Status ≥ 70 * Completed any systemic therapy (excluding endocrine therapy, which may be ongoing) at least one week prior to planned start of SBRT (two weeks preferred) and must have no plans to initiate systemic therapy for at least one week following end of SBRT (two weeks preferred). * Able to understand and be willing to sign an IRB approved written informed consent document (or legally authorized representative, if applicable).
Exclusion criteria
* Past history of radiotherapy within the projected treatment field of any of the disease sites to be treated by MRI-guided, gated, and/or online adaptive SBRT * Current central nervous systemic disease. * Widespread progressive disease, i.e., more than three sites of progressive disease (note that more than three sites of disease are permitted provided there are no more than three sites of progressive disease). * Actively receiving any investigational agents. * Presence of uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. * Pregnant and/or breastfeeding. Patients of childbearing potential must have a negative pregnancy test within 14 days of study entry. * Medical contraindication to undergoing MR imaging.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Feasibility of providing online, adaptive MRI-guided and gated SBRT as measured by the ability to deliver a full course of MRI-guided SBRT in at least 80% of eligible patients who have completed simulation and planning | Completion of all enrolled patients (up to 2 years) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Safety as measured by late toxicities | 91 days to 6 months post completion of treatment | the descriptions and grading scales found in the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 will be utilized for all toxicity reporting. |
| Response rate | 3 months post treatment | -Response will be measured using the revised Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1) \[Eur J Ca 45:228-247, 2009\]. |
| In-field control rate | 6 months post treatment | — |
| Local control rate | 3 months post treatment | — |
| Regional control rate | 3 months post treatment | — |
| Safety as measured by acute toxicities | Up to 90 days post completion of treatment | the descriptions and grading scales found in the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 will be utilized for all toxicity reporting. |
| Progression-free survival (PFS) rate | 6 months post treatment | -PFS is defined as the duration of time from start of treatment to time of progression or death, whichever occurs first. |
| Disease-free survival (DFS) rate | 6 months post treatment | -The length of time that a patient survives without any signs or symptoms of their cancer |
| Overall survival (OS) rate | 6 months post treatment | — |
| Patient-reported health-related quality of life (HRQOL) | 6 months post treatment | * HRQOL will be measured using the EORTC QLQ-C30 and QLQ-OV28 questionnaires. * European Organization for Research and Treatment of Cancer (EORTC) QLQ-30 consists of 28 questions with answers that range from 1 (Not At All) to 4 (Very Much) and 2 questions that range from 1 (Very Poor) to 7 (Excellent) * EORTC QLQ-OV28 consists of 28 questions ranging with answers from 1 (Not At All) to 4 (Very Much) |
| CA-125 response levels | 6 months post treatment | — |
| Distant control rate | 3 months post treatment | — |
Countries
United States
Outcome results
None listed